TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Bioxyne Limited ( (AU:BXN) ).
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has dispatched its second shipment of Australian-manufactured GMP MDMA capsules to support a clinical trial by the Victorian Government’s Eastern Health. This trial investigates MDMA-assisted psychotherapy for patients with co-occurring PTSD and borderline personality disorder, highlighting the growing demand and Bioxyne’s positioning as Australia’s first domestic supplier of pharmaceutical-grade MDMA and psilocybin. The initiative is part of a broader trend towards psychedelic-assisted therapies, which are gaining acceptance globally, and is expected to drive significant growth alongside Bioxyne’s core medicinal cannabis and consumer health businesses.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical company focusing on the development and commercialization of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, it is expanding into the production of psychedelic compounds for therapeutic use. Breathe Life Sciences, founded in 2018, is a GMP-licensed manufacturer and wholesaler of controlled substances, including medicinal cannabis, Psilocybin, and MDMA, with operations in Australia, Japan, the UK, and Czechia.
Average Trading Volume: 3,664,650
Technical Sentiment Signal: Buy
Current Market Cap: A$81.02M
For an in-depth examination of BXN stock, go to TipRanks’ Overview page.